Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | PTPRB | P23467 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046217 | 0.90 | CTSL (0.44) | CTSLCTSBCTSSCTSKPTPRB | |
| SCHEMBL7046421 | 0.90 | USP30 (0.39) | CTSLCTSBCTSSCTSKPTPRB | |
| SCHEMBL7046969 | 0.84 | PTPRB (0.39) | PTPRBPTPN11STSMMP13USP30 | |
| SCHEMBL7044976 | 0.84 | PTPRB (0.38) | PTPRBPTPN11STSUSP30GPR119 | |
| SCHEMBL7047991 | 0.82 | CTSL (0.47) | CTSLCTSBCTSSCTSKPTPRB | |
| SCHEMBL7048358 | 0.74 | SMN1; SMN2 (0.38) | MAPT | |
| SCHEMBL7183810 | 0.73 | CTSL (0.42) | CTSLCTSBCTSSCTSKPTPRB | |
| SCHEMBL7049413 | 0.72 | CTSL (0.41) | CTSLCTSBCTSSCTSKPTPRB | |
| SCHEMBL7049419 | 0.72 | CTSL (0.47) | CTSLCTSBCTSSCTSKPTPRB | |
| SCHEMBL7046155 | 0.72 | USP30 (0.41) | CTSLCTSBCTSSCTSKPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSL 18/4885CTSB 11/4885CTSS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.